CRABP1 is associated with a poor prognosis in breast cancer: adding to the complexity of breast cancer cell response to retinoic acid

Liu, Rong-Zong; Garcia, Elizabeth; Glubrecht, Darryl D.; Poon, Ho Yin; Mackey, John R.; Godbout, Roseline

doi:10.1186/s12943-015-0380-7

Molecular Cancer

Table 1 Clinicopathological associations of CRABP1 and CRABP2 in human breast cancers

From: CRABP1 is associated with a poor prognosis in breast cancer: adding to the complexity of breast cancer cell response to retinoic acid

	Factor	Classification	cDNA microarray			Tissue microarray
			n	Geometric mean	p	Cytoplasmic immunoreactivity					Nuclear immunoreactivity
			n	Geometric mean	p	Negative		Positive		p	Negative		Positive		p
CRABP1	ER	Negative	64	4.16	<0.0001	20		21		0.0058	28		13		0.0583
		Positive	112	0.67	<0.0001	49		15		0.0058	54		10		0.0583
	PR	Negative	82	2.80	<0.0001	27		25		0.0040	37		15		0.1031
		Positive	94	0.67	<0.0001	42		11		0.0040	45		8		0.1031
	Her2	Negative	146	1.39	0.2038	53		31		0.3119	63		21		0.1512
		Positive	30	0.94	0.2038	16		5		0.3119	19		2		0.1512
	Triple negative	No	120	0.72	<0.0001	52		17		0.0051	59		10		0.0142
		Yes	56	4.63	<0.0001	17		19		0.0051	23		13		0.0142
	Death	No	119	1.13	0.1641	49		18		0.0532	53		9		0.8078
		Yes	57	1.74	0.1641	20		18		0.0532	29		14		0.8078
	Recurrence	No	88	1.21	0.6020	36		10		0.0225	39		7		0.1615
		Yes	88	1.40	0.6020	33		26		0.0225	43		16		0.1615
	Nodal status	pN0	69	0.81	0.021	26		14		1.0000	31		9		1.0000
		pN1-3	107	1.21	0.021	42		22		1.0000	51		14		1.0000
	Cancer stage	I	45	1.63	0.1635	21		3		0.0133	22		2		0.0919
		II–III	131	1.21	0.1635	48		33		0.0133	60		21		0.0919
	Nuclear grade	Low	44	0.34	<0.0001	20		4		0.0050	24		0		0.0015
		High	132	2.04	<0.0001	49		32		0.0050	58		23		0.0015
	Mitotic grade	Low	78	0.48	<0.0001	36		7		0.0016	41		2		0.0003
		High	98	2.91	<0.0001	33		29		0.0016	41		21		0.0003
	Arch grade	Low	29	0.76	0.0929	10		0		0.0145	10		0		0.1129
		High	147	1.45	0.0929	59		36		0.0145	72		23		0.1129
	Overall grade	Low	56	0.41	<0.0001	25		5		0.0221	30		0		0.0002
		High	120	2.24	<0.0001	44		31		0.0221	52		23		0.0002
						Cytoplasmic immunoreactivity					Nuclear immunoreactivity
						0	1	2	3	p	0	1	2	3	p
CRABP2	ER	Negative	64	0.63	<0.0001	7	18	13	3	0.0613	5	11	13	12	0.0010
		Positive	112	1.37	<0.0001	3	29	19	14	0.0613	0	6	25	34	0.0010
	PR	Negative	82	0.73	0.0002	8	23	17	4	0.0371	5	12	19	16	0.0070
		Positive	94	1.40	0.0002	2	24	15	13	0.0371	0	5	19	30	0.0070
	Her2	Negative	146	0.95	0.0369	9	39	24	13	0.6762	4	15	30	36	0.8405
		Positive	30	1.53	0.0369	1	8	8	4	0.6762	1	2	8	10	0.8405
	Triple negative	No	120	1.32	p < 0.0001	4	30	22	14	0.1545	1	6	28	35	0.0019
		Yes	56	0.61	p < 0.0001	6	17	10	3	0.1545	4	11	10	11	0.0019
	Death	No	119	1.12	0.2089	4	34	21	9	0.1819	1	12	28	27	0.0843
		Yes	57	0.87	0.2089	6	13	11	8	0.1819	4	5	10	19	0.0843
	Recurrence	No	88	1.02	0.8998	3	26	13	5	0.1837	1	11	18	17	0.1567
		Yes	88	1.04	0.8998	7	21	19	12	0.1837	4	6	20	29	0.1567
	Nodal status	pN0	69	1.78	0.0819	4	20	14	3	0.2813	2	8	19	12	0.1308
		pN1-3	107	1.07	0.0819	6	27	18	14	0.2813	3	9	19	34	0.1308
	Cancer stage	I	45	0.81	0.0895	3	13	7	2	0.5660	2	4	11	8	0.5062
		II–III	131	1.12	0.0895	7	34	25	15	0.5660	3	13	27	38	0.5062
	Nuclear grade	Low	44	1.12	0.5981	1	12	7	4	0.7638	1	2	11	10	0.5616
		High	132	1.05	0.5981	9	35	25	13	0.7638	4	15	27	36	0.5616
	Mitotic grade	Low	78	1.11	0.4743	2	19	13	10	0.2547	0	4	17	23	0.0618
		High	98	0.98	0.4743	8	28	19	7	0.2547	5	13	21	23	0.0618
	Arch grade	Low	29	1.20	0.4399	1	6	3	1	0.8747	0	1	3	7	0.5014
		High	147	1.00	0.4399	9	41	29	16	0.8747	5	16	35	39	0.5014
	Overall grade	Low	56	1.04	0.9369	1	15	10	5	0.5695	0	3	14	14	0.2344
		High	120	1.03	0.9369	9	32	22	12	0.5695	5	14	24	32	0.2344

Back to article page

ISSN: 1476-4598

Contact us

General enquiries: journalsubmissions@springernature.com